Key Points
- CEO Snehal Patel bought 4,100 shares of GLSI on Dec. 18 at $12.62 ( ~$51,742), raising his direct holdings to 5,592,202 shares (~$70.6M), a 0.07% increase.
- Patel has been steadily accumulating stock—21,600 shares bought across four trades between Oct. 31 and Dec. 18 for roughly $201,000, at prices ranging about $8.37–$12.62—signaling insider buying activity.
- GLSI opened at $13.01, trades near its 52-week high (high $14.47 / low $7.78) with a $180.2M market cap and negative PE, while analysts show a consensus Hold and a $42 price target amid mixed ratings.
Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) CEO Snehal Patel acquired 4,100 shares of the stock in a transaction on Thursday, December 18th. The stock was bought at an average price of $12.62 per share, with a total value of $51,742.00. Following the transaction, the chief executive officer directly owned 5,592,202 shares in the company, valued at approximately $70,573,589.24. This represents a 0.07% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Snehal Patel also recently made the following trade(s):
- On Tuesday, November 25th, Snehal Patel bought 4,600 shares of Greenwich LifeSciences stock. The stock was bought at an average cost of $8.37 per share, with a total value of $38,502.00.
- On Friday, November 7th, Snehal Patel purchased 10,600 shares of Greenwich LifeSciences stock. The shares were bought at an average cost of $8.43 per share, for a total transaction of $89,358.00.
- On Friday, October 31st, Snehal Patel purchased 2,300 shares of Greenwich LifeSciences stock. The stock was bought at an average cost of $9.26 per share, with a total value of $21,298.00.
Greenwich LifeSciences Price Performance
GLSI stock opened at $13.01 on Friday. The company has a 50 day moving average price of $9.22 and a 200 day moving average price of $10.25. Greenwich LifeSciences, Inc. has a fifty-two week low of $7.78 and a fifty-two week high of $14.47. The stock has a market capitalization of $180.19 million, a PE ratio of -8.91 and a beta of 1.61.
Greenwich LifeSciences (NASDAQ:GLSI - Get Free Report) last announced its quarterly earnings data on Friday, November 14th. The company reported ($0.30) EPS for the quarter, meeting analysts' consensus estimates of ($0.30). As a group, equities analysts expect that Greenwich LifeSciences, Inc. will post -0.8 earnings per share for the current fiscal year.
Analyst Ratings Changes
Separately, Weiss Ratings reiterated a "sell (e+)" rating on shares of Greenwich LifeSciences in a research report on Tuesday, October 14th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $42.00.
Read Our Latest Report on GLSI
Institutional Trading of Greenwich LifeSciences
Institutional investors and hedge funds have recently made changes to their positions in the business. Bank of America Corp DE boosted its position in shares of Greenwich LifeSciences by 22.3% in the 4th quarter. Bank of America Corp DE now owns 7,262 shares of the company's stock worth $82,000 after purchasing an additional 1,322 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in Greenwich LifeSciences by 15.5% in the first quarter. Charles Schwab Investment Management Inc. now owns 19,007 shares of the company's stock valued at $181,000 after purchasing an additional 2,552 shares during the last quarter. HighTower Advisors LLC acquired a new position in Greenwich LifeSciences in the first quarter valued at about $147,000. Strs Ohio acquired a new position in Greenwich LifeSciences in the first quarter valued at about $177,000. Finally, Rhumbline Advisers boosted its holdings in Greenwich LifeSciences by 48.7% during the first quarter. Rhumbline Advisers now owns 9,673 shares of the company's stock worth $92,000 after buying an additional 3,168 shares during the last quarter. Institutional investors own 4.16% of the company's stock.
Greenwich LifeSciences Company Profile
(
Get Free Report)
Greenwich LifeSciences, Inc (NASDAQ: GLSI) is a clinical-stage biotechnology company focused on the development of novel immune modulators for the treatment of cancer and autoimmune diseases. The company's product pipeline includes candidates engineered to activate or regulate key components of the innate and adaptive immune systems, with programs advancing through preclinical and early-stage clinical studies.
Headquartered in Greenwich, Connecticut, Greenwich LifeSciences conducts its research and development activities primarily in the United States.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
